Organon & Co.
OGN
Classificação em ações
#4352
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing... Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Preço da ação
$13.75
Última sincronização: 2026-10-19
Valor de mercado
$3.61B
Variação (1 dia)
-0.11%
Variação (1 ano)
48.76%
País
US
Negociar Organon & Co. (OGN)
Categoria
Healthcare
Lucros da Organon & Co. (OGN)
Lucros em Jun 2026 TTM: $491.00M
De acordo com os últimos relatórios financeiros da Organon & Co., os ganhos atuais da empresa são de $491.00M. Em 2024, a empresa teve ganhos de $807.00M, um aumento em relação a aos ganhos de 2023, que foram de $673.00M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Organon & Co. de 2017 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $491.00M | 15.53% |
| 2025 | $425.00M | -47.34% |
| 2024 | $807.00M | 19.91% |
| 2023 | $673.00M | -40.02% |
| 2022 | $1.12B | -26.62% |
| 2021 | $1.53B | -44.44% |
| 2020 | $2.75B | -25.54% |
| 2019 | $3.70B | 35.43% |
| 2018 | $2.73B | -11.94% |
| 2017 | $3.10B | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $33.60B | 6,742.28% |
US
|
|
| $17.74B | 3,512.42% |
US
|
|
| $8.70B | 1,671.69% |
US
|
|
| $5.95B | 1,111.41% |
US
|
|
| $21.39B | 4,256.07% |
CH
|
